Cat. No.: DAB-0012266
Product Information | |
---|---|
Clonality | Monoclonal |
Host Species | Rabbit |
Product Description | Monoclonal antibodies are produced by immunizing animals with synthetic phosphopeptides or peptides corresponding to residues surrounding: Tyr1003, Tyr1234/1235, Tyr1349, or near the carboxy terminus of human Met protein. Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide or peptide corresponding to residues surrounding Tyr472 and Tyr307 of human Gab1. Polyclonal antibodies are purified by protein A and peptide affinity chromatography. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Gene Description | Met, a high affinity tyrosine kinase receptor for hepatocyte growth factor, is a disulfide-linked heterodimer made of 45 kDa α- and 145 kDa β-subunits. The α-subunit and the amino-terminal region of the β-subunit form the extracellular domain. The remainder of the β-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl and PI3 kinase. These fundamental events are important for all of the biological functions involving Met kinase activity. Addition of a phosphate at cytoplasmic Tyr1003 is essential for ubiquitination and Met protein degradation. Phosphorylation of Tyr1234/1235 in the Met kinase domain is critical to kinase activation. Phosphorylation of Tyr1349 in the Met cytoplasmic domain provides a direct binding site for Gab1. Altered Met levels and/or tyrosine kinase activities are found in several types of tumors, including renal, colon and breast cancers. Thus, Met is an attractive cancer therapeutic and diagnostic target. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at +4 °C short term (1-2 weeks). Store at -20 °C long term. |
Storage Buffer | Constituent: 100% PBS |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.